Compare BBLG & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBLG | CRIS |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2M | 976.1K |
| IPO Year | 2014 | 2000 |
| Metric | BBLG | CRIS |
|---|---|---|
| Price | $0.28 | $0.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $30.33 |
| AVG Volume (30 Days) | 409.0K | ★ 5.9M |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.13 | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,070,000,000.00 | $9,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $604.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.27 | $0.33 |
| 52 Week High | $4.78 | $2,880.00 |
| Indicator | BBLG | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 33.16 |
| Support Level | N/A | $0.33 |
| Resistance Level | $0.48 | $1.60 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 10.91 | 7.04 |
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.